Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research.
The share prose rose after the company had announced that Fluidigm mass cytometry technology and the Maxpar Direct Immune Profiling Assay are being utilized in a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with COVID-19. — https://finance.yahoo.com/news/multi-stu...
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $5,86;
stop-loss — $5,41.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!